- DHR +0.56%
Search results
- 266.20Add to watchlist+1.49 (+0.56%)At close: Fri. Sep 6, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Market closed
- Open265.52High270.10Low265.07
- Mkt Cap192.25BP/E (TTM)49.02Div & Yield1.08 & 0.41%
- Prev. Close264.7152 Wk. Low182.0952 Wk. High281.70
What analysts are sayingTop storiesIs Danaher Corporation (DHR) the Best Cancer Stock to Buy Now?Yahoo Finance · 5 days ago- DHR +0.56%
Navigating Market Uncertainty: Intrinsic Value of Danaher CorpYahoo Finance · 5 days agoRelated stocks
We’re Danaher - a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. From our environment to our associates, we’re determined to create positive impact that accelerates greater progress.
Danaher Corporation is an American global conglomerate founded in 1984 by brothers Steven and Mitchell Rales. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.
Our business directory organizes all of Danaher’s businesses in one place. Danaher is comprised of more than 15 diverse businesses across Biotechnology, Diagnostics, and Life Sciences. Learn more about the Danaher companies.
Find the latest Danaher Corporation (DHR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Danaher is a leading global life sciences and diagnostics innovator, helping to solve many of the world’s most important health challenges. Ultimately improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow.
Danaher’s proven business system drives performance. We are proud to be a Fortune 200 company, and our stock has outperformed the S&P 500 index by more than 2,000% over the past 25 years.
May 9, 2015 · Danaher Confirms Third Quarter and Full Year 2024 Guidance. Danaher Corporation (NYSE: DHR) (the "Company") confirmed its previously issued guidance for the third quarter and full year 2024 ahead of a previously scheduled analyst event.